Abstract: The present invention relates to a pharmaceutical composition for preventing or treating otitis media with effusion comprising a fraction of Melissa officinalis leaf extract as an effective ingredient.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present invention relates to a composition comprising paeonol of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for inhibiting angiogenesis, or for enhancing radiosensitization. The present invention also relates to novel use of paeonol of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a composition for inhibiting angiogenesis, or for the manufacture of a composition for enhancing radiosensitization. Also, the present invention relates to a method for inhibiting angiogenesis which comprises administrating to a subject in need thereof an effective amount of paeonol of formula (I) or a pharmaceutically acceptable salt thereof, or a method for enhancing radiosensitization which comprises administrating an effective amount of paeonol of formula (I) or pharmaceutically acceptable salts thereof to a subject in need of radiotherapy.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present application describes an ethyl acetate fraction of Melissa leaf having excellent angiogenesis and MMP inhibitory activities, and a composition comprising the same.

Abstract: The present invention relates to a composition containing Horse chestnut extract that inhibits angiogenesis and matrix metalloproteinase activity. The Horse chestnut extract of the present invention inhibits angiogenesis and activity of matrix metalloproteinase, so that it can be applied to treat and prevent disease related to angiogenesis and/or matrix metalloproteinase.

Abstract: The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition.

Abstract: The present invention provides an MMP-inhibitory composition comprising chalcone or its derivatives. They inhibit the MMPs in collagenase subfamily as well as those in gelatinase subfamily. The MMP inhibitory activity of chalcone derivatives was similar to or greater than that of parent compound, chalcone. Chalcone or its derivatives of the present invention inhibit activity of matrix metalloproteinase, so that it can be applied to treat and prevent diseases related to matrix metalloproteinase.

Abstract: The present invention relates to a composition comprising Melissa leaf extract that inhibits angiogenesis and matrix metalloproteinase activity. The Melissa leaf extract of the present invention inhibits angiogenesis and activity of matrix metalloproteinase, so that it can be applied to treat or prevent diseases related to angiogenesis and matrix metalloproteinase. The composition of the present invention comprising Melissa leaf extract may also comprise more than one component of the other anti-angiogenic, anti-cancer, anti-inflammatory and anti-aging components. This particular composition comprising Melissa leaf extract can be used for pharmaceutical, dietetic and/or cosmetic purposes.

Abstract: The present invention relates to a composition for the prevention or treatment of diseases associated with angiogenesis, and in detail, to a composition comprising the extract of Cnidium officinale Makino or the fraction thereof for the prevention or treatment of diseases associated with angiogenesis. The present invention also provides 3-butyl-7-hydroxyphthalide, vanillin, coniferyl ferulate, and falcarindiol as active compounds. The composition of the present invention inhibits angiogenesis, so that it can be applied to the prevention or treatment of diseases related to angiogenesis, such as arthritis, diabetic retinopathy, psoriasis, and cancer.

Abstract: The present invention relates to a composition comprising paeonol of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for inhibiting angiogenesis, or for enhancing radiosensitization. The present invention also relates to novel use of paeonol of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a composition for inhibiting angiogenesis, or for the manufacture of a composition for enhancing radiosensitization. Also, the present invention relates to a method for inhibiting angiogenesis which comprises administrating to a subject in need thereof an effective amount of paeonol of formula (I) or a pharmaceutically acceptable salt thereof, or a method for enhancing radiosensitization which comprises administrating an effective amount of paeonol of formula (I) or pharmaceutically acceptable salts thereof to a subject in need of radiotherapy.

Abstract: The present invention provides a human serum albumin-TIMP2 fusion protein having the amino acid sequence set forth in SEQ ID NO. 10, a polynucleotide encoding the same and a vector comprising the polynucleotide, a host cell transformed with the vector, a method for producing the human serum albumin-TIMP2 fusion protein and a pharmaceutical composition comprising the human serum albumin-TIMP2 fusion protein. The human serum albumin-TIMP2 fusion protein is stable and retains the activity of TIMP2, thus it can be used as a pharmaceutical composition to treat diseases related to angiogenesis and/or metastasis of cancer cells.

Abstract: The present invention relates to a composition for the prevention or treatment of diseases associated with angiogenesis, and in detail, to a composition comprising the extract of Cnidium officinale Makino or the fraction thereof for the prevention or treatment of diseases associated with angiogenesis. The present invention also provides 3-butyl-7-hydroxyphthalide, vanillin, coniferyl ferulate, and falcarindiol as active compounds. The composition of the present invention inhibits angiogenesis, so that it can be applied to the prevention or treatment of diseases related to angiogenesis, such as arthritis, diabetic retinopathy, psoriasis, and cancer.